Best Ophthalmology podcasts — Eye and vision research (Updated February 2018; image)
Related podcasts: Science Medicine Retina Cataract Health and Well-Being Glaucoma Cornea Business Eyes Radiology Optometry Spine Medical Brain Health Tech Education US Government Duke Health Diabetes And Endocrinology  
public [subscription 1120]
show episodes
Medscape Ophthalmology Podcast
Latest medical news and features from Medscape Ophthalmology
As Seen From Here
the Ophthalmology podcast
OIS Podcast
Welcome to the Ophthalmology Innovation Podcast where you get candid conversations with the leaders & drivers of ophthalmic innovation.
Loading …
show series
Guest: David Huang, MD, PhD Weeks Professor of Ophthalmic Research Casey Eye Institute Oregon Health & Science University Portland, OR
OIS - the Ophthalmology Innovation Summit - is introducing a new OIS Launch program to raise awareness and inform early adopters on recently launched and soon to be approved therapies. The inaugural OIS Launch is an invitation-only dinner program led by Paul Karpecki, OD, Joe Boorady, OD, and Emmett Cunningham, MD, who have developed a program ...…
New CEO Antony Mattessich says Ocular Therapeutix has learned its mistakes after receiving two CRLs from the FDA. With new leadership and a clear vision, the company is ready to push forward as a full-fledged biopharmaceutical company.
Guests: Kathleen Digre, MD Professor, Ophthalmology & Visual Science University of Utah Salt Lake City, UT Eduardo C. Alfonso, MD Professor and Chairman Bascom Palmer Eye Institute Miami, FL
A veteran of bioelectronic medicine, Khalid Ishaque joined Pixium Vision four years ago after recognizing the promise of using implantable devices to restore vision. Today, the company is developing not one - but two - technologies that could help restore sight.
Apple made headlines with a promise to spend repatriated dollars on R&D in the US. In this week’s podcast we talk with three Wall Street analysts to understand what we can expect to see from pharma and Medtech companies following the monster acquisitions of Juno, Kite et al. What ophthalmology companies might be acquisition targets? Will Medtec ...…
Should a terminally ill cancer patient who asks for cataract surgery to improve his quality of life be granted his wish?
Cedric Francois, president and CEO, discusses his debut performance at JP Morgan in which he laid out the company’s plans for a Phase III trial of APL-2, the promising treatment for geographic atrophy. Francois shared the details of the trial, talked about going public, and shared one of the least recognized – but most important – challenges fa ...…
A look at the evidence supporting vitamin therapy for the most common cause of vision loss in US adults: age-related macular degeneration.
As Seen From Here
Guests: Gabrielle Buitendijk and Annemarie Colijn Erasmus University Medical School Rotterdam, The Netherlands
Roger Longman, CEO of Real Endpoints, a firm assisting pharma companies with their pricing strategies, discusses the state of the value-based pricing market while lending some insights on what specialty drug companies like Spark can do to get payers on board with higher prices.
A recently approved shingles vaccine seems to be more effective in preventing the virus. Drs Rapuano and Meghpara from Wills Eye Hospital discuss its role for patients.
Oyster Point Pharma CEO Jeff Nau sheds some light on the new dry eye start-up, which is tapping much of the leadership and investment team that made Oculeve successful. He also talks about his own experiences leading high-profile clinical programs at Ophthotech and Genentech. What lessons will he bring into his new CEO role?…
Guests: Carol Shields, MD Director of the Ocular Oncology Service Wills Eye Hospital Philadelphia, PA Earl Randy Craven, MD Associate Professor of Ophthalmology Wilmer Eye Institute Bethesda, MD
Guest: Matt Schlenker, MD Toronto, Ontario Canada
Michael Abramoff, MD, PhD, president, director, and co-founder of IDx, tells how the start-up is using artificial intelligence to better diagnose diabetic retinopathy. The company hopes to get FDA approval of its IDx-DR system.
In part one of a two-part podcast, OIS co-chair and Clarus Funds managing director Emmett Cunningham, Jr., MD, PhD, MPH, delivers a 360-degree review of ophthalmology’s more promising pipelines. To download a copy of an extended version of the Year in Review report delivered at OIS@AAO click here.
Guest: Matt Schlenker, MD Toronto, Ontario Canada
In part one of a two-part podcast, OIS co-chair and Clarus Funds managing director Emmett Cunningham, Jr., MD, delivers a 360-degree review of ophthalmology’s more promising pipelines.
In interviews at OIS@AAO, we talk with Robert Dempsey, global head of Shire’s ophthalmic business, about the international launch of Xiidra. Joseph Boorady, CEO and president of TearScience, lays out the company’s plans since being acquired by Johnson & Johnson Vision. Finally, Tom Gadek, president and CEO of TearSolutions, explains how he’s ho ...…
Guests: Baruch Kuppermann, MD, PhD Chair, Department of Ophthalmology UC Irvine Irvine, CA Theo Seiler, MD, PhD Head, Institute for Refractive and Ophthalmic Surgery Zurich, Switzerland
Brent Saunders, president, CEO, and chairman of global leader Allergan, sits down at OIS@AAO to discuss what impact the pending loss of the Restasis patent could have on the company. He also rejects talk of Allergan breaking off its ophthalmology business, saying the company is in the sector to stay.…
Eric Donnenfeld, MD, founding partner of Ophthalmology Consultants of Long Island, explains how his practice will use a capital infusion from growth equity firm Blue Sea Capital. Dr. Donnenfeld also opines on the growing cooperation - and competition - between ophthalmologists and optometrists. Plus, he explains how he uses CheckedUp to engage ...…
Guest: Chirag Pradip Shah, MD, MPH Assistant Professor Tufts University School of Medicine Boston MA
OIS co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, talks about OIS’ evolution over nearly a decade of meetings. The addition of Breakfast Breakout Sessions and Master Classes has opened opportunities for speakers and attendees. Dr. Cunningham, a partner at Clarus, also walks us through the agenda of next week’s OIS@AAO in New Orleans. This ye ...…
Aerie Pharmaceuticals scored an impressive win at the recent FDA advisory panel, getting a thumbs up for the approval of Rhopressa. In this interview, CEO Vince Anido explains how Aerie plans to move forward with its lead glaucoma product. He also tells how its new drug-delivery technology will fit into its plans. In addition, we get an update ...…
Ophthalmology companies have had a difficult time targeting AMD lately. Newcomer Gemini Therapeutics is bringing a “multimodal approach” to identify new targets in the complement system, with an eye toward developing specific treatments for patients with connected genetic codes. CEO, president, and co-founder James McLaughlin explains how Gemin ...…
Guests: Marcony Santhiago, MD, PhD Professor of Ophthalmology Federal University of Rio de Janeiro and the University of Sao Paulo, Brazil Warren Hill, MD East Valley Ophthalmology Mesa, AZ
CEO Paul Chaney details the company’s plans to move forward with $11 million in new capital. He also recounts how his unplanned entry into ophthalmology led him to appreciate how special the specialty truly is. Chaney also explains why PanOptica’s pursuit of an eye-drop-based treatment for AMD and DR is personal.…
With $3 million to invest in first-time funds, impact investor ExSight Capital built a promising and productive portfolio that included gene therapy company RetroSense. Now, ExSight co-founder and partner Firas M. Rahhal, MD, says the firm is planning to raise a much larger fund that could elevate its standing as a seed-stage investor in ophtha ...…
Guest: Chris Rudnisky, MD, MPH Professor, Department of Ophthalmology University of Alberta Edmonton, Alberta Canada
Pravin Dugel, MD, managing partner, Retinal Consultants of Arizona, delivers a frank overview of the pipeline of experimental retinal drugs. The next year could be critical for retinal disease as combination therapies and other products push through late-stage clinical trials. What technologies show the most promise? What advances have surprise ...…
Christy Shaffer, PhD, general partner at Hatteras Venture Partners, didn’t have a career map that led her into the corner office at Inspire Pharmaceuticals or into the partnership at Hatteras Venture Partners. But the clinical scientist grew to succeed in both roles. Dr. Shaffer led Inspire when the company conceived and then built out its opht ...…
Guests: Gerd Auffarth, MD Chairman, Dept. of Ophthalmology University of Heidelberg Heidelberg, Germany Robert Edward T. Ang, MD Asian Eye Institute Makati City, Philippines
Accomplished ophthalmologist Mark Blumenkranz, MD, moved early into the Digital Health space by co-founding Digisight, one of the more advanced efforts in ophthalmology. Six years, later, Dr. Blumenkranz still sees enormous opportunity so he’s working with the FDA and top clinical societies to hold a one-day workshop for physicians, investors, ...…
In 2011, Cal Roberts, MD, got an unexpected call from Brent Saunders, then head of Bausch & Lomb. Saunders asked if Dr. Roberts would trade a thriving ophthalmology practice to serve as chief medical officer at the eye care giant. Today, Dr. Roberts is thrilled with the decision, and other ophthalmology companies are following the example, brin ...…
As Seen From Here
Guest: Sung Chul (Sean) Park, MD Assistant Professor of Ophthalmology Director, Glaucoma Clinic and Research Manhattan Eye, Ear and Throat Hospital Hofstra Northwell School of Medicine New York, NY
Even moderate improvements in hyperglycemia, hypertension, and hyperlipidemia can yield substantial results.
M. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, shares details of the institute’s detection of apoptosing retinal cells (DARC) scan – which employs a new retinal biomarker. The DARC system, which will undergo further trials, could allow for earlier detection of retinal disease in patients ...…
Charles Semba, MD, is one of the more recognized and accomplished figures in development of new ophthalmology treatments. He has played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery technology. Now the chief medical officer at Graybug Vision, Dr. Semba is working to develop a technology tha ...…
Dr Christopher Rapuano discusses the likely outcomes and recovery for this newly approved treatment for keratoconus.
Guests: Soon Phaik Chee, MD Associate Professor Singapore National Eye Centre Singapore Mingguang He, MD, PhD Professor of Ophthalmic Epidemiology University of Melbourne and Centre for Eye Research Australia Director of WHO Collaborating Centre for Prevention of Blindness (Australia) Melbourne, Australia…
OIS@ASRS co-chairs Emmett Cunningham Jr., MD, Mark S. Humayun, MD, PhD, and John Pollack, MD, took a few minutes to share their thoughts on the second OIS@ASRS. Dr. Humayun, the outgoing ASRS president, shares details on his next undertaking – finding a way to measure the value of vision protection. Meanwhile, Dr. Pollack highlights one of his ...…
OIS Co-chair Emmett T. Cunningham Jr., MD, PhD, MPH, managing director, Clarus Funds, walks us through the agenda of Thursday’s OIS@ASRS. What areas of retina will dominate the headlines for the next 12 months?
Last week, Johnson & Johnson announced plans to acquire TearScience, maker of a line of products capable of diagnosing and treating Meibomian gland dysfunction, a leading cause of Dry Eye. Ashley McEvoy , Company Group Chairman for Johnson & Johnson Vision, explains where TearScience will fit into J&J if the deal is completed and what the globa ...…
Dr Christopher Rapuano sorts through the updated recommendations for dry eye provided in the recently published report of the Tear Film & Ocular Surface Society International Dry Eye Workshop II.
Allegro Ophthalmics expects to deliver some positive news about its Phase II DEL MAR trial that is evaluating the safety and efficacy of Luminate as an adjunctive therapy with anti-VEGFs in patients with diabetic macular edema (DME). Could the news put the company in a position for an initial public offering?…
Guest: Laura M. Periman, MD Seattle, WA
Join in as two ophthalmologists have an in-depth discussion about vancomycin-associated hemorrhagic occlusive retinal vasculitis, including its diagnosis, treatment, and prognosis.
Series preference

Google login Twitter login Classic login